pubs.acs.org/joc
approximately 3- to 4-fold increase in cytotoxicity compared
A Concise Palladium-Catalyzed Carboamination
Route to (()-Tylophorine
to its natural (R)-(-)-isomer (avg. GI50 13 vs 43 nM,
respectively).2b
In the past decade, a number of concise synthetic prepara-
tions of racemic tylophorine have appeared in the literature,3
and a few approaches to the discrete R- and S-enantiomers of
1 have also been published.4 We nevertheless sought to
contribute our own novel approach, based on the palla-
dium-catalyzed carboamination process recently established
by Wolfe and co-workers.5 As both absolute configurations
of tylophorine still serve as viable starting points for struc-
tural analogue modifications for drug discovery investiga-
tions,2 we decided to demonstrate the feasibility for a natural
product synthesis of racemic tylophorine using the Wolfe
carboamination strategy. This communication summarizes
our results toward this goal.
Lana M. Rossiter, Meagan L. Slater, Rachel E. Giessert,
Samuel A. Sakwa, and R. Jason Herr*
Medicinal Chemistry Department, Albany Molecular
Research, Inc. (AMRI), P.O. Box 15098, 26 Corporate Circle,
Albany, New York 12212-5098
Received October 1, 2009
A palladium-catalyzed carboamination reaction of γ-amino-
alkenes 2 with aryl bromides has recently been developed by the
Wolfe group to define a general synthesis of substituted pyrro-
lidines 3 (n= 1), as well as larger heterocycles (Scheme 1).5
This process relies on the ability of amines to form a
metallo-amide species 4 with a reactive arylpalladium sub-
strate to direct the metal toward a tethered olefinic moiety.
The palladium intermediate may then undergo an insertion
reaction into the olefin, generating new organometallic
intermediate 5 that contains the newly formed heterocycle.
Reductive elimination of the metal from the species 5 may
then provide the amine heterocycle 3 and regenerate the
active palladium species to perpetuate the catalytic cycle.
While the earliest published method was limited to N-aryl
nucleophiles, more recent communications have demon-
strated the use of carbamate substrates 2 (e.g., PG = Cbz,
Boc) to provide protected products 4 that can be easily
converted into the free amine under mild conditions.6,7
To test the feasibility of the method toward an approach to
racemic tylophorine, we first explored the carboamination
reaction between the two commercially available coupling
precursors 9-bromophenanthrene (6a, X = Br) and tert-
butyl pent-4-enylcarbamate (7), as shown in Scheme 2.
A total synthesis of the racemic natural product tylophorine
[(()-1] has been demonstrated using the palladium-cata-
lyzed carboamination method developed by Wolfe and co-
workers. In this case, an electron-rich aryl bromide 18 was
prepared in four steps and subjected to palladium-catalyzed
Wolfe carboamination conditions with olefinic carbamate 7
to provide the racemic 2-(arylmethyl)pyrrolidine (()-19 in
good yield and was further elaborated to racemic tylopho-
rine. This application of the Wolfe carboamination protocol
as a key step to construct a natural product provides further
evidence of the utility of the method.
Tylophorine [(R)-(-)-1, Figure 1] is a phenanthroindoli-
zidine alkaloid that was first isolated in 1935 from the
perennial climbing plant Tylophora indica1 and has recently
re-emerged as an alkaloid target family of interest, due
largely to its cytotoxic activity by a novel mechanism of
action.2 Its synthetically derived (S)-(þ)-antipode has gene-
rated even greater interest due to its superior cell growth
inhibition activity versus its natural isomer. For instance, in
three carcinoma cell lines, (S)-(-)-tylophorine exhibited an
(3) For the most recent examples, see: (a) Yamashita, S.; Kurono, N.;
Senboku, H.; Tokuda, M.; Orito, K. Eur. J. Org. Chem. 2009, 1173.
(b) McIver, A.; Young, D. D.; Deiters, A. Chem. Commun. 2008, 39, 4750.
(c) Wang, K.-L.; Lue, M.-Y.; Wang, Q.-M.; Huang, R.-Q. Tetrahedron 2008,
64, 7504. (d) Chuang, T.-H.; Lee, S.-J.; Yang, C.-W.; Wu, P.-L. Org. Biomol.
Chem. 2006, 4, 860. (e) Li, Z.; Jin, Z.; Huang, R. Synthesis 2001, 16, 2365.
(4) For the most recent examples, see: (a) Zeng, W.; Chemler, S. R. J. Org.
Chem. 2008, 73, 6045. (b) Wang, K.; Wang, Q.; Huang, R. J. Org. Chem. 2007,
€
72, 8416. (c) Furstner, A.; Kennedy, J. W. J. Chem.;Eur. J. 2006, 12, 7398.
(1) (a) Wu, P.-L.; Rao, K. V.; Su, C.-H.; Kuoh, C.-S.; Wu, T.-S.
Heterocycles 2002, 57, 2401. (b) Abe, F.; Iwase, Y.; Yamauchi, T.; Honda,
K.; Hayashi, N. Phytochemistry 1995, 39, 695. (c) Govindachari, T. R.;
Lakshmikantham, M. V.; Nagarajan, K.; Pai, B. R. Chem. Ind. 1957, 1484.
(d) Ratnagiriswaran, A. N.; Venkatachalam, K. Ind. J. Med. Res. 1935,
22, 433.
(d) Jin, Z.; Li, S. P.; Wang, Q. M.; Huang, R. Q. Chin. Chem. Lett. 2004, 15,
1164.
(5) (a) Wolfe, J. P. Synlett 2008, 2913. (b) Wolfe, J. P. Eur. J. Org. Chem.
2007, 571. (c) Ney, J. E.; Hay, M. B.; Yang, Q.; Wolfe, J. P. Adv. Synth. Catal.
2005, 347, 1614.
(6) (a) Bertrand, M. B.; Neukom, J. D.; Wolfe, J. P. J. Org. Chem. 2008,
73, 8851. (b) Bertrand, M. B.; Wolfe, J. P. Org. Lett. 2007, 9, 3073.
(c) Bertrand, M. B.; Leathen, M. L.; Wolfe, J. P. Org. Lett. 2007, 9, 457.
(d) Bertrand, M. B.; Wolfe, J. P. Tetrahedron 2005, 61, 6447.
(7) For related palladium- and copper-catalyzed carboamination work,
see: (a) Chemler, S. R. Org. Biomol. Chem. 2009, 7, 3009. (b) Rosewall, C. F.;
Sibbald, P. A.; Liskin, D. V.; Michael, F. E. J. Am. Chem. Soc. 2009, 131,
(2) (a) Yang, X.; Shi, Q.; Liu, Y.-N.; Zhao, G.; Bastow, K. F.; Lin, J.-C.;
Yang, S.-C.; Yang, P.-C.; Lee, K.-H. J. Med. Chem. 2009, 52, 5262. (b) Gao,
€
W.; Chen, A. P.-C.; Leung, C.-H.; Gullen, E. A.; Furstner, A.; Shi, Q.; Wei,
L.; Lee, K.-H.; Cheng, Y.-C. Bioorg. Med. Chem. Lett. 2008, 18, 704.
(c) Banwell, M. G.; Bezos, A.; Burns, C.; Kruszelnicki, I.; Parish, C. R.;
Su, S.; Sydnes, M. O. Bioorg. Med. Chem. Lett. 2006, 16, 181. (d) Gao, W.;
Lam, W.; Zhong, S.; Kaczmarek, C.; Baker, D. C.; Cheng, Y.-C. Cancer Res.
2004, 64, 678. (e) Strk, D.; Lykkeberg, A. K.; Christensen, J.; Budnik, B. A.;
Abe, F.; Jaroszewski, J. W. J. Nat. Prod. 2002, 65, 1299.
€
~
9488. (c) Hovelmann, C. H.; Streuff, J.; Brelot, L.; Muniz, K. Chem.
Commun. 2008, 2334. (d) Minatti, A.; Muniz, K. Chem. Soc. Rev. 2007, 36,
~
1142. (e) Chemler, S. R.; Fuller, P. H. Chem. Soc. Rev. 2007, 36, 1153.
9554 J. Org. Chem. 2009, 74, 9554–9557
Published on Web 11/17/2009
DOI: 10.1021/jo902114u
r
2009 American Chemical Society